This page summarizes trial-derived R&D investment signals for Multiple System Atrophy (MSA) using the local Clinical Trials Index pipeline snapshot refreshed on 2026-03-14T04:21:18. The intent is to track portfolio concentration, sponsor mix, and underrepresented mechanism areas that can inform quarterly planning. [1]
| Metric | Value |
|---|---|
| Total tracked trials | 429 |
| Active trials (recruiting/active/not-yet-recruiting) | 153 (35.7%) |
| Completed trials | 189 (44.1%) |
| Late-stage representation (Phase 3/4) | 43 (10.0%) |
| Biomarker-forward programs | 28 (14.4%) |
| Combination-therapy signals | 0 (0.0%) |
| Category | Trial Count | Share |
|---|---|---|
| Active/Recruiting | 82 | 42.3% |
| Not Yet Recruiting | 4 | 2.1% |
| Recruiting | 55 | 28.4% |
| Active Not Recruiting | 18 | 9.3% |
| Enrolling By Invitation | 5 | 2.6% |
| Historical | 93 | 47.9% |
| Completed | 76 | 39.2% |
| Terminated | 14 | 7.2% |
| Withdrawn | 2 | 1.0% |
| No Longer Available | 1 | 0.5% |
| Unknown | 18 | 9.3% |
Key Insight: Approximately 42.3% of registered Multiple System Atrophy (MSA) trials are currently active, while 47.9% have reached a terminal status (completed, terminated, or withdrawn). The 18 unknown-status entries reflect trials with stale registry records.
The following table shows trial status updates over the past 12 months, based on last update date in ClinicalTrials.gov:
| Month | Total Updates | Active/Recruiting | Historical |
|---|---|---|---|
| 2025-03 | 3 | 3 | 0 |
| 2025-04 | 7 | 5 | 2 |
| 2025-05 | 6 | 4 | 2 |
| 2025-06 | 7 | 6 | 1 |
| 2025-07 | 5 | 2 | 3 |
| 2025-08 | 2 | 0 | 2 |
| 2025-09 | 4 | 4 | 0 |
| 2025-10 | 4 | 4 | 0 |
| 2025-11 | 6 | 5 | 1 |
| 2025-12 | 6 | 6 | 0 |
| 2026-01 | 8 | 8 | 0 |
| 2026-02 | 6 | 6 | 0 |
| 2026-03 | 8 | 6 | 2 |
Key Insight: Trial activity peaked in 2026-01 with 8 updates. Active/recruiting trials consistently reflect sustained research investment in Multiple System Atrophy (MSA) therapeutic development.
| Mechanism Cluster | Trial Count | Share |
|---|---|---|
| Genetic / gene-targeted | 21 | 10.8% |
| Alpha-synuclein pathology | 17 | 8.8% |
| Mitochondrial biology | 15 | 7.7% |
| Amyloid biology | 5 | 2.6% |
| Neurotransmitter systems | 4 | 2.1% |
| Neuroinflammation | 4 | 2.1% |
| Metabolic pathways | 2 | 1.0% |
| Synaptic dysfunction | 2 | 1.0% |
Mechanism coverage should be interpreted as a directional signal from registry metadata, not a complete map of all preclinical and translational investment streams.
| Sponsor Type | Trial Count | Share |
|---|---|---|
| Academic/Medical | 109 | 56.2% |
| Other | 47 | 24.2% |
| Industry | 32 | 16.5% |
| Public (NIH/Gov) | 4 | 2.1% |
| Foundation/Nonprofit | 2 | 1.0% |
Top sponsors by trial volume:
| Sponsor | Trial Count | Share |
|---|---|---|
| University Hospital, Bordeaux | 9 | 4.6% |
| Vanderbilt University Medical Center | 9 | 4.6% |
| Vanderbilt University | 9 | 4.6% |
| University Hospital, Toulouse | 6 | 3.1% |
| NYU Langone Health | 5 | 2.6% |
| Massachusetts General Hospital | 3 | 1.5% |
This landscape is designed for recurring quarterly updates. Each cycle should include a refresh of trial records, a rerun of sponsor-type and mechanism-gap summaries, and a brief adjudication of whether the observed distribution reflects true scientific opportunity or only metadata coverage effects in public registries. Where possible, this page should be interpreted together with detailed pages in Clinical Trials Index, disease pages, and mechanism pages to avoid over-indexing on simple count-based proxies.